The Roche Group reported sales of CHF 58.7 billion ($68.6 billion) in 2023, a decline of 7% from a year earlier in Swiss francs. At constant exchange rates however, the results showed a small 1% rise. The decline reflected the absence of sales for Covid-19 products in the most recent period – a reflection of the global recovery from the pandemic. During 2023, Roche also faced biosimilar competition for three of its legacy products – the cancer medicines Herceptin, Avastin and Rituxan. Rituxan is also approved for autoimmune diseases.
